Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
DURECT Corporation stock logo
DRRX
DURECT
$1.91
-1.0%
$1.43
$0.48
$2.64
$59.94M0.92582,423 shs2.79 million shs
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
$6.21
-1.9%
$5.16
$3.51
$16.95
$54.89M0.35191,091 shs79,538 shs
Inotiv, Inc. stock logo
NOTV
Inotiv
$1.39
-13.7%
$1.89
$1.15
$6.48
$55.31M4.15346,449 shs964,470 shs
PreveCeutical Medical Inc. stock logo
PRVCF
PreveCeutical Medical
$0.02
-4.8%
$0.02
$0.01
$0.03
$13.07M0.49132,372 shs1,000 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
DURECT Corporation stock logo
DRRX
DURECT
-1.04%-1.55%+2.14%+198.44%+27.33%
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
-1.90%-12.29%+64.72%+42.43%-42.89%
Inotiv, Inc. stock logo
NOTV
Inotiv
-13.66%-12.03%-25.67%-40.85%+8.59%
PreveCeutical Medical Inc. stock logo
PRVCF
PreveCeutical Medical
-4.80%-9.54%-12.80%-18.66%+115.84%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
DURECT Corporation stock logo
DRRX
DURECT
$1.91
-1.0%
$1.43
$0.48
$2.64
$59.94M0.92582,423 shs2.79 million shs
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
$6.21
-1.9%
$5.16
$3.51
$16.95
$54.89M0.35191,091 shs79,538 shs
Inotiv, Inc. stock logo
NOTV
Inotiv
$1.39
-13.7%
$1.89
$1.15
$6.48
$55.31M4.15346,449 shs964,470 shs
PreveCeutical Medical Inc. stock logo
PRVCF
PreveCeutical Medical
$0.02
-4.8%
$0.02
$0.01
$0.03
$13.07M0.49132,372 shs1,000 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
DURECT Corporation stock logo
DRRX
DURECT
-1.04%-1.55%+2.14%+198.44%+27.33%
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
-1.90%-12.29%+64.72%+42.43%-42.89%
Inotiv, Inc. stock logo
NOTV
Inotiv
-13.66%-12.03%-25.67%-40.85%+8.59%
PreveCeutical Medical Inc. stock logo
PRVCF
PreveCeutical Medical
-4.80%-9.54%-12.80%-18.66%+115.84%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
DURECT Corporation stock logo
DRRX
DURECT
2.00
HoldN/AN/A
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
2.80
Moderate Buy$34.00447.50% Upside
Inotiv, Inc. stock logo
NOTV
Inotiv
3.00
Buy$5.00259.71% Upside
PreveCeutical Medical Inc. stock logo
PRVCF
PreveCeutical Medical
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest PRVCF, DRRX, KPTI, and NOTV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/12/2025
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$42.00 ➝ $25.00
7/29/2025
DURECT Corporation stock logo
DRRX
DURECT
Northland Capmk
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-BuyHold
7/16/2025
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuyNeutral
7/11/2025
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$27.00
(Data available from 9/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
DURECT Corporation stock logo
DRRX
DURECT
$2.03M29.21N/AN/A$0.29 per share6.59
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
$145.24M0.37N/AN/A($22.10) per share-0.28
Inotiv, Inc. stock logo
NOTV
Inotiv
$490.74M0.10$1.34 per share1.04$6.55 per share0.21
PreveCeutical Medical Inc. stock logo
PRVCF
PreveCeutical Medical
N/AN/AN/AN/A($0.01) per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
DURECT Corporation stock logo
DRRX
DURECT
-$8.32M-$0.10N/AN/AN/A-96.19%-259.16%-71.78%11/12/2025 (Estimated)
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
-$76.42M-$14.59N/AN/AN/A-90.02%N/A-84.28%11/4/2025 (Estimated)
Inotiv, Inc. stock logo
NOTV
Inotiv
-$108.44M-$2.70N/AN/AN/A-15.63%-15.74%-3.28%N/A
PreveCeutical Medical Inc. stock logo
PRVCF
PreveCeutical Medical
-$860KN/A0.00N/AN/AN/A-821.91%N/A

Latest PRVCF, DRRX, KPTI, and NOTV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
DURECT Corporation stock logo
DRRX
DURECT
-$0.13-$0.07+$0.06-$0.07$0.32 million$0.45 million
8/11/2025Q2 2025
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
-$3.80-$4.32-$0.52-$4.32$37.92 million$37.93 million
8/6/2025Q3 2025
Inotiv, Inc. stock logo
NOTV
Inotiv
-$0.15-$0.12+$0.03-$0.51$127.05 million$130.70 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
DURECT Corporation stock logo
DRRX
DURECT
N/AN/AN/AN/AN/A
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
N/AN/AN/AN/AN/A
Inotiv, Inc. stock logo
NOTV
Inotiv
N/AN/AN/AN/AN/A
PreveCeutical Medical Inc. stock logo
PRVCF
PreveCeutical Medical
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
DURECT Corporation stock logo
DRRX
DURECT
N/A
0.98
0.95
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
N/A
0.99
0.94
Inotiv, Inc. stock logo
NOTV
Inotiv
2.71
1.29
0.96
PreveCeutical Medical Inc. stock logo
PRVCF
PreveCeutical Medical
N/A
0.01
0.01

Institutional Ownership

CompanyInstitutional Ownership
DURECT Corporation stock logo
DRRX
DURECT
28.03%
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
66.44%
Inotiv, Inc. stock logo
NOTV
Inotiv
18.17%
PreveCeutical Medical Inc. stock logo
PRVCF
PreveCeutical Medical
N/A

Insider Ownership

CompanyInsider Ownership
DURECT Corporation stock logo
DRRX
DURECT
3.20%
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
2.98%
Inotiv, Inc. stock logo
NOTV
Inotiv
7.80%
PreveCeutical Medical Inc. stock logo
PRVCF
PreveCeutical Medical
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
DURECT Corporation stock logo
DRRX
DURECT
8031.05 million30.06 millionOptionable
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
3808.67 million8.41 millionOptionable
Inotiv, Inc. stock logo
NOTV
Inotiv
2,07534.35 million31.68 millionOptionable
PreveCeutical Medical Inc. stock logo
PRVCF
PreveCeutical Medical
N/A570.65 millionN/ANot Optionable

Recent News About These Companies

PRVCF PreveCeutical Medical Inc. - Seeking Alpha
PreveCeutical Announces Non-Brokered Private Placement

New MarketBeat Followers Over Time

Media Sentiment Over Time

DURECT stock logo

DURECT NASDAQ:DRRX

$1.91 -0.02 (-1.04%)
As of 09/10/2025 04:00 PM Eastern

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.

Karyopharm Therapeutics stock logo

Karyopharm Therapeutics NASDAQ:KPTI

$6.21 -0.12 (-1.90%)
Closing price 09/10/2025 04:00 PM Eastern
Extended Trading
$6.19 -0.02 (-0.32%)
As of 09/10/2025 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Inotiv stock logo

Inotiv NASDAQ:NOTV

$1.39 -0.22 (-13.66%)
Closing price 09/10/2025 04:00 PM Eastern
Extended Trading
$1.44 +0.06 (+3.96%)
As of 09/10/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line. The RMS segment engages in commercial production and sales of research models, diets, bedding, and bioproducts. The company offers research and discovery services, including computational toxicology, disease pharmacology, DMPK, safety pharmacology, discovery bioanalysis, exploratory, surgical models and medical device, and cell and molecular biology; non-clinical safety assessment includes general and genetic toxicology, regulated bioanalysis, carcinogenicity studies, and development and reproductive toxicology; pathology services, such as histology, digital, clinical, and medical device pathology; bioanalysis includes nonregulated discovery bioanalysis, biotherapeutics, and regulated preclinical and clinical bioanalysis; proteomics; and consulting services, as well as model and research services. The company operates in the United States, the Netherlands, and internationally. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was incorporated in 1974 and is headquartered in West Lafayette, Indiana.

PreveCeutical Medical stock logo

PreveCeutical Medical OTCMKTS:PRVCF

$0.02 0.00 (-4.80%)
As of 09/10/2025 12:29 PM Eastern

PreveCeutical Medical Inc., a health sciences company, engages in the development of options for preventive and curative therapies utilizing organic and nature identical products. Its pipeline products include Cannabinoid Sol-Gel Delivery, a cannabinoid-based nose-to-brain delivery system that provides relief from various indications, including pain, inflammation, seizures, and neurological disorders; Non-Addictive Analgesic for pain management; BSV Peptide Program that targets cancer progression; and Dual Gene Therapy for type 2 diabetes and obesity. PreveCeutical Medical Inc. is headquartered in West Vancouver, Canada.